| 摘要 |
<p>Helicobacter pylori has been implicated as a contributing factor in a number of pathological conditions, including acute (type B) gastritis, gastric and duodenal ulcers, gastric adenocarcinoma, and gastric lymphoma. The present invention relates to the use of di- or oligosaccharide glycosides containing at least one terminal L-fucose unit for the preparation of pharmaceutical compositions for the treatment or prophylaxis in humans of conditions involving infection by Helicobacter pylori in the human gastric mucosa, as well as a method of treating such conditions using the di- or oligosaccharide glycosides by administering to a patient in need thereof an effective amount of a di- or oligosaccharide glycoside comprising at least one terminal L-fucose unit.</p> |
